Sellas Life Sciences

Price & Volume

Stats

52W Range	$0.49-$1.72
Market Cap	$76M
Shares Short	7M

Financials

Revenue (12 Mos)	$0
Revenue Growth (YoY)	-82.5%
Gross Profit (12 Mos)	$900,000
Diluted EPS	-$0.67

News

Yahoo Finance • last year

SELLAS Life Sciences Reaches Target Enrollment ex-China in Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia

Yahoo Finance • last year

SELLAS Life Sciences Receives Favorable FDA Type C Meeting Feedback on Chemistry, Manufacturing, and Controls (CMC) Biologics License Application (BLA) Filing Strategy for Galinpepimut-S (GPS)

Yahoo Finance • last year

SELLAS Life Sciences Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annual Global Meeting

Yahoo Finance • last year

SELLAS Life Sciences to Present Final Data from Phase 1/2 Study of Galinpepimut-S in Combination with Keytruda® (pembrolizumab) in Patients with WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annual Global Meeting

About

CEO	Dr. Angelos M. Stergiou M.D., ScD h.c.
CFO	Mr. John Thomas Burns CPA
Address	Times Square Tower, New York, NY, United States, 10036
Sector	Healthcare
Industry	Biotechnology
Full-Time Employees	16